Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 12, 2026, 12:30 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 73–96 of 830 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Safety and Pharmacokinetics in Healthy Volunteer Subjects Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

A Pharmacokinetics and Safety of Methylphenidate HCl in Healthy Japanese Adult Male Volunteers

NCT01202734
View directory record Official record
Conditions
Healthy
Interventions
Methylphenidate HCl
Drug
Lead sponsor
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Industry
Eligibility
20 Years to 35 Years · Male only
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated May 16, 2014 · Synced Oct 12, 2026, 12:30 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Pharmacokinetics - Pharmacodynamic Study of HT-2157 in Healthy Subjects and in Patients With Major Depressive Disorder

NCT01413932
View directory record Official record
Conditions
Healthy Volunteers (Part 1), Major Depressive Disorder (Part 2)
Interventions
HT-2157, Placebo
Drug
Lead sponsor
Dart NeuroScience, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011 – 2012
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Dec 16, 2015 · Synced Oct 12, 2026, 12:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Intrapulmonary Pharmacokinetics of XNW4107, Imipenem and Cilastatin in Healthy Subjects

NCT04802863
View directory record Official record
Conditions
Bacterial Infections
Interventions
XNW4107, Imipenem/Cilastatin
Drug
Lead sponsor
Evopoint Biosciences Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Phoenix, Arizona
Source: ClinicalTrials.gov public record
Updated Feb 16, 2023 · Synced Oct 12, 2026, 12:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Of Single Doses Of PF-06291826 (Tafamidis) In Japanese And Western Subjects

NCT01369836
View directory record Official record
Conditions
Healthy
Interventions
Tafamidis meglumin, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2011
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Sep 13, 2011 · Synced Oct 12, 2026, 12:30 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

To Evaluate Safety, Tolerability, Plasma Drug Levels And Other Biological Effects In Healthy Volunteers

NCT01045863
View directory record Official record
Conditions
Healthy
Interventions
PF-03382792 Cohort 1, PF-03382792 Cohort 2, PF-03382792, Food Effect cohort, CSF cohort
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Aug 4, 2010 · Synced Oct 12, 2026, 12:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY3009104(Baricitinib) for Healthy Subjects

NCT01247350
View directory record Official record
Conditions
Healthy Volunteer
Interventions
LY3009104, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
20 Years to 65 Years
Enrollment
34 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010 – 2011
U.S. locations
1
States / cities
Honolulu, Hawaii
Source: ClinicalTrials.gov public record
Updated Apr 13, 2018 · Synced Oct 12, 2026, 12:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Pharmacokinetics of VNRX-5133 in the Epithelial Lining Fluid of Healthy Adult Subjects

NCT03870490
View directory record Official record
Conditions
Healthy Subjects
Interventions
VNRX-5133 + cefepime
Drug
Lead sponsor
Venatorx Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019
U.S. locations
1
States / cities
Hartford, Connecticut
Source: ClinicalTrials.gov public record
Updated May 6, 2019 · Synced Oct 12, 2026, 12:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Ziresovir in Healthy Subjects

NCT04788017
View directory record Official record
Conditions
Healthy Subjects
Interventions
Ziresovir, Placebo
Drug · Other
Lead sponsor
Shanghai Ark Biopharmaceutical Co., Ltd.
Industry
Eligibility
18 Years to 55 Years
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
Secaucus, New Jersey
Source: ClinicalTrials.gov public record
Updated Feb 15, 2022 · Synced Oct 12, 2026, 12:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Drug-Drug Interaction Study of HBI-3000 and Paroxetine in Healthy Adult Male and Female Subjects

NCT04650542
View directory record Official record
Conditions
Drug-drug Interaction
Interventions
HBI-3000, Paroxetine
Drug
Lead sponsor
HUYABIO International, LLC.
Industry
Eligibility
18 Years to 50 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 15, 2022 · Synced Oct 12, 2026, 12:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of EDG-7500 in Healthy Adults

NCT06011317
View directory record Official record
Conditions
Healthy Subjects
Interventions
EDG-7500, Placebo
Drug
Lead sponsor
Edgewise Therapeutics, Inc.
Industry
Eligibility
18 Years to 59 Years
Enrollment
84 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
2
States / cities
Tempe, Arizona • Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jul 16, 2024 · Synced Oct 12, 2026, 12:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY3015014 in Healthy Participants With High Cholesterol

NCT01671085
View directory record Official record
Conditions
Healthy Volunteers, Hypercholesterolemia
Interventions
LY3015014, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
1
States / cities
Miramar, Florida
Source: ClinicalTrials.gov public record
Updated Mar 15, 2019 · Synced Oct 12, 2026, 12:30 AM EDT
Terminated Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Evaluate PK and Safety of Proellex® in Females With Various Stages of Impaired Renal Function and Healthy Females

NCT00787618
View directory record Official record
Conditions
Renal Impairment
Interventions
50 mg Proellex
Drug
Lead sponsor
Repros Therapeutics Inc.
Industry
Eligibility
18 Years to 48 Years · Female only
Enrollment
6 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2009
U.S. locations
4
States / cities
Miami, Florida • Orlando, Florida • Minneapolis, Minnesota + 1 more
Source: ClinicalTrials.gov public record
Updated Aug 25, 2014 · Synced Oct 12, 2026, 12:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Single Dose RO6811135 in Healthy Volunteers

NCT01676584
View directory record Official record
Conditions
Healthy Volunteer
Interventions
RO6811135, placebo
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years to 45 Years
Enrollment
56 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Nov 2, 2016 · Synced Oct 12, 2026, 12:30 AM EDT
Active, not recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

A Study of AMG 732 in Healthy Participants and Participants With Thyroid Eye Disease

NCT06401044
View directory record Official record
Conditions
Thyroid Eye Disease
Interventions
AMG 732, Placebo
Drug · Other
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 65 Years
Enrollment
94 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2027
U.S. locations
12
States / cities
Little Rock, Arkansas • Newport Beach, California • Jacksonville, Florida + 9 more
Source: ClinicalTrials.gov public record
Updated Aug 10, 2026 · Synced Oct 12, 2026, 12:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of ABBV-1088 Oral Dose in Healthy Adult Participants.

NCT06414798
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Drug: ABBV-1088, Drug: Placebo for ABBV-1088
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Grayslake, Illinois
Source: ClinicalTrials.gov public record
Updated Feb 19, 2025 · Synced Oct 12, 2026, 12:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety And Tolerability Study Of BID Titration Scheme With PF-05089771

NCT01772264
View directory record Official record
Conditions
Healthy
Interventions
PF-05089771, Placebo
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated May 10, 2013 · Synced Oct 12, 2026, 12:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pharmacokinetic and Safety Study of Cenicriviroc and Acid Reducing Agents When Dosed Alone or in Combination

NCT02684799
View directory record Official record
Conditions
Healthy
Interventions
Cenicriviroc, Omeprazole, Famotidine
Drug
Lead sponsor
Tobira Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
48 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Nov 24, 2017 · Synced Oct 12, 2026, 12:30 AM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers

Clinical Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of LEZ763

NCT01619332
View directory record Official record
Conditions
Type II Diabetes
Interventions
Placebo, Sitagliptin, LEZ763
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 65 Years
Enrollment
220 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2013
U.S. locations
6
States / cities
Chula Vista, California • Miami, Florida • Orlando, Florida + 3 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2020 · Synced Oct 12, 2026, 12:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study of Osilodrostat (LCI699) in Healthy Volunteers and Subjects With Impaired Hepatic Function

NCT02372084
View directory record Official record
Conditions
Hepatic Impairment
Interventions
osilodrostat
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
33 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
3
States / cities
Miami, Florida • Orlando, Florida • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Dec 19, 2020 · Synced Oct 12, 2026, 12:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Single and Multiple Ascending Dose Study to Evaluate the Safety, Pharmacokinetics, and Target Engagement of BMS-986147 in Healthy Subjects

NCT02293629
View directory record Official record
Conditions
Healthy
Interventions
BMS-986147, Placebo matching BMS-986147
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years to 45 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated May 19, 2015 · Synced Oct 12, 2026, 12:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

MAD Study Evaluating the Safety, Tolerability, and Pharmacokinetics of Cavosonstat (N91115) in Healthy Subjects (SNO-9)

NCT02934139
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Cavosonstat, Placebo
Drug · Other
Lead sponsor
Nivalis Therapeutics, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Lakewood, Colorado
Source: ClinicalTrials.gov public record
Updated Jan 31, 2017 · Synced Oct 12, 2026, 12:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Ascending Dose Escalation Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of TNX-1500 in Healthy Subjects

NCT07473752
View directory record Official record
Conditions
Phase 1 First-in-human Study Involving Healthy Subjects
Interventions
TNX-1500, Placebo: USP 0.9% sterile saline for injection, Keyhole Limpet Hemocyanin (KLH)
Drug · Biological
Lead sponsor
Tonix Pharmaceuticals, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Mar 16, 2026 · Synced Oct 12, 2026, 12:30 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Multiple Ascending Dose Study to Assess the Pharmacokinetics, Safety, and Tolerability of Orally Administered SYN 020

NCT05045833
View directory record Official record
Conditions
Enteritis Caused by Radiation
Interventions
SYN-020 Delayed Release Capsule
Drug
Lead sponsor
Theriva Biologics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
West Bend, Wisconsin
Source: ClinicalTrials.gov public record
Updated Apr 21, 2022 · Synced Oct 12, 2026, 12:30 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

A Single Ascending Dose Trial of CVL-936 in Healthy Subjects

NCT04232878
View directory record Official record
Conditions
Substance Use Disorders (SUD)
Interventions
CVL-936, Matching Placebo
Drug
Lead sponsor
Cerevel Therapeutics, LLC
Industry
Eligibility
18 Years to 50 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Marlton, New Jersey
Source: ClinicalTrials.gov public record
Updated Jun 22, 2020 · Synced Oct 12, 2026, 12:30 AM EDT